Pharmacological Characterization of a Novel Factor Xa Inhibitor, FXV673

By Chu V.   Brown K.   Colussi D.   Gao J.   Bostwick J.   Kasiewski C.   Bentley R.   Morgan S.   Guertin K.   Pauls H.W.   Gong Y.   Zulli A.   Perrone M.H.   Dunwiddie C.T.   Leadley R.J.  

Thrombosis Research, Vol. 103, Iss. 4, 2001-08 ,pp. : 309-324

Elsevier

Access to resources Recommend Favorite

Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031)

By Post J.M.   Sullivan M.E.   Abendschein D.   Ewing J.   Hinchman J.W.   Light D.R.  

Thrombosis Research, Vol. 105, Iss. 4, 2002-02 ,pp. : 347-352

Elsevier

Access to resources Recommend Favorite

Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor

By Becker Richard  

Journal of Thrombosis and Thrombolysis, Vol. 32, Iss. 2, 2011-08 ,pp. : 183-187

Springer Publishing Company

Access to resources Recommend Favorite

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

By Wong Pancras  

Journal of Thrombosis and Thrombolysis, Vol. 31, Iss. 4, 2011-05 ,pp. : 478-492

Springer Publishing Company

Access to resources Recommend Favorite

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

By Hara T.   Yokoyama A.   Morishima Y.   Kunitada S.  

Thrombosis Research, Vol. 80, Iss. 1, 1995-10 ,pp. : 99-104

Elsevier

Access to resources Recommend Favorite